Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Publications / Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.

Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.

  • Hruban RH
  • Adsay NV
  • Albores-Saavedra J
  • Anver MR
  • Biankin AV
  • Boivin GP
  • Furth EE
  • Furukawa T
  • Klein A
  • Klimstra DS
  • Kloppel G
  • Lauwers GY
  • Longnecker DS
  • Luttges J
  • Maitra A
  • Offerhaus GJ
  • PĂ©rez-Gallego L
  • Redston M
  • Tuveson DA

16397221

Cancer Res.. 2006 Jan 66 (1).

Several diverse genetically engineered mouse models of pancreatic exocrine neoplasia have been developed. These mouse models have a spectrum of pathologic changes; however, until now, there has been no uniform nomenclature to characterize these changes. An international workshop, sponsored by The National Cancer Institute and the University of Pennsylvania, was held from December 1 to 3, 2004 with the goal of establishing an internationally accepted uniform nomenclature for the pathology of genetically engineered mouse models of pancreatic exocrine neoplasia. The pancreatic pathology in 12 existing mouse models of pancreatic neoplasia was reviewed at this workshop, and a standardized nomenclature with definitions and associated images was developed. It is our intention that this nomenclature will standardize the reporting of genetically engineered mouse models of pancreatic exocrine neoplasia, that it will facilitate comparisons between genetically engineered mouse models and human pancreatic disease, and that it will be broad enough to accommodate newly emerging mouse models of pancreatic neoplasia.